Human Amnion Epithelial Cells Reduce Fetal Brain Injury in Response to Intrauterine Inflammation

The Ritchie Centre, Monash Institute of Medical Research, Clayton, Vic., Australia.
Developmental Neuroscience (Impact Factor: 2.7). 04/2013; 35(2-3). DOI: 10.1159/000346683
Source: PubMed


Intrauterine infection, such as occurs in chorioamnionitis, is a principal cause of preterm birth and is a strong risk factor for neurological morbidity and cerebral palsy. This study aims to examine whether human amnion epithelial cells (hAECs) can be used as a potential therapeutic agent to reduce brain injury induced by intra-amniotic administration of lipopolysaccharide (LPS) in preterm fetal sheep. Pregnant ewes underwent surgery at approximately 110 days of gestation (term is approx. 147 days) for implantation of catheters into the amniotic cavity, fetal trachea, carotid artery and jugular vein. LPS was administered at 117 days; hAECs were labeled with carboxyfluorescein succinimidyl ester and administered at 0, 6 and 12 h, relative to LPS administration, into the fetal jugular vein, trachea or both. Control fetuses received an equivalent volume of saline. Brains were collected 7 days later for histological assessment of brain injury. Microglia (Iba-1-positive cells) were present in the brain of all fetuses and were significantly increased in the cortex, subcortical and periventricular white matter in fetuses that received LPS, indicative of inflammation. Inflammation was reduced in fetuses that received hAECs. In LPS fetuses, the number of TUNEL-positive cells was significantly elevated in the cortex, periventricular white matter, subcortical white matter and hippocampus compared with controls, and reduced in fetuses that received hAECs in the cortex and periventricular white matter. Within the fetal brains studied there was a significant positive correlation between the number of Iba-1-immunoreactive cells and the number of TUNEL-positive cells (R(2) = 0.19, p < 0.001). The administration of hAECs protects the developing brain when administered concurrently with the initiation of intrauterine inflammation.

Download full-text


Available from: Timothy JM Moss, Oct 07, 2015
1 Follower
19 Reads
  • Source
    • "In developing preterm fetal sheep, we have recently published data on the utility of hAECs to reduce organ injury and to elucidate the mechanisms by which hAECs have their effect (Vosdoganes et al., 2011; Hodges et al., 2012; Yawno et al., 2013). In particular, we have been interested in novel therapies to reduce or ameliorate inflammation-induced preterm lung and brain injury. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the research, clinical and wider community there is great interest in the use of stem cells to reduce the progression, or indeed repair brain injury. Perinatal brain injury may result from acute or chronic insults sustained during fetal development, during the process of birth, or in the newborn period. The most readily identifiable outcome of perinatal brain injury is cerebral palsy, however this is just one consequence in a spectrum of mild to severe neurological deficits. As we review, there are now clinical trials taking place worldwide targeting cerebral palsy with stem cell therapies. It will likely be many years before strong evidence-based results emerge from these trials. With such trials underway, it is both appropriate and timely to address the physiological basis for the efficacy of stem-like cells in preventing damage to, or regenerating, the newborn brain. Appropriate experimental animal models are best placed to deliver this information. Cell availability, the potential for immunological rejection, ethical and logistical considerations, together with the propensity for native cells to form terratomas, make it unlikely that embryonic or fetal stem cells will be practical. Fortunately, these issues do not pertain to the use of human amnion epithelial cells (hAECs), or umbilical cord blood (UCB) stem cells that are readily and economically obtained from the placenta and umbilical cord discarded at birth. These cells have the potential for transplantation to the newborn where brain injury is diagnosed or even suspected. We will explore the novel characteristics of hAECs and undifferentiated UCB cells, as well as UCB-derived endothelial progenitor cells and mesenchymal stem cells, and how immunomodulation and anti-inflammatory properties are principal mechanisms of action that are common to these cells, and which in turn may ameliorate the cerebral hypoxia and inflammation that are final pathways in the pathogenesis of perinatal brain injury.
    Frontiers in Neuroscience 10/2013; 7(article 194):194. DOI:10.3389/fnins.2013.00194 · 3.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is a chronic autoimmune disease that involves inflammation, axonal damage, and demyelination of the brain and spinal cord. Whilst there are a number of treatments currently available for this often debilitating disease, they all target the immune system with variable efficacy and are often associated with potentially serious side effects. Most compellingly is that whilst these drugs can prevent relapses and minimize long-term disability, they are not curative, do not aid in the regeneration of damaged neural tissue or protect the CNS from neurodegeneration associated with progressive forms of MS. As such there is an urgent need for the development of new therapies that are effective for patients with relapsing–remitting as well as progressive MS and can not only prevent CNS injury but assist with repair. One such potential therapy is stem cell transplantation. A number of different stem cell types have been shown to be efficacious in murine models of MS, and thus clinical trials are being undertaken to investigate the efficacy in the clinic. A novel stem cell source that is gaining attention is human amnion epithelial cells (hAECs). These cells have been shown to suppress inflammation, migrate to inflamed sites within the CNS, engraft and differentiate toward neural lineages. Given their immunosuppressive and neuroregenerative potential, hAECs are attractive candidates for the treatment of MS and other neurodegenerative disorders that affect the CNS.
    Perinatal Stem Cells, 01/2014: pages 231-242; , ISBN: 978-1-4939-1117-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The transition to newborn life in preterm infants is complicated by immature cardiovascular and respiratory systems. Consequently, preterm infants often require respiratory support immediately after birth. Although aeration of the lung underpins the circulatory transition at birth, positive pressure ventilation can adversely affect cardio-respiratory function during this vulnerable period, reducing pulmonary blood flow and left ventricular output. Further, pulmonary volutrauma is known to initiate pulmonary inflammatory responses, resulting in remote systemic involvement.Pediatric Research (2014); doi:10.1038/pr.2014.40.
    Pediatric Research 03/2014; 75(6). DOI:10.1038/pr.2014.40 · 2.31 Impact Factor
Show more